ANGO News Alert Angiodynamics (ANGO) 16.86 11/13/2014 17:31:

New Post Public Reply Private Reply Replies (0) Message Board

Nov 13, 2014 at 6:31 PM

Angiodynamics (ANGO) 16.86 $ANGO

Thoratec (THOR) Down to Strong Sell on Growing Headwinds - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 12:20PM CST
On Nov 11, 2014, Zacks Investment Research downgraded Thoratec Corp. (THOR) to a Zacks Rank #5 (Strong Sell).
ABMD: 33.48 (-0.12), EW: 124.55 (+1.60), THOR: 28.40 (+0.48), ANGO: 16.86 (-0.12)

Abiomed (ABMD) Hits 52-Week High on Strong Q2 Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 10:10AM CST
Shares of Abiomed, Inc. (ABMD) have been on the rise since it reported impressive second-quarter fiscal 2015 (ended Sep 30, 2014) results on Oct 30.
ABMD: 33.48 (-0.12), FLDM: 29.88 (-0.01), GMED: 22.92 (-0.24), ANGO: 16.86 (-0.12)

Mettler-Toledo (MTD) Tops Q3 Earnings on Revenue Strength - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 8:34AM CST
Mettler-Toledo International Inc. (MTD) reported adjusted earnings per share (EPS) of $2.95 for the third quarter of fiscal 2014, which beat the Zacks Consensus Estimate of $2.86. Adjusted EPS also improved 13% from the year-ago quarter.
ABMD: 33.48 (-0.12), FLDM: 29.88 (-0.01), ANGO: 16.86 (-0.12), MTD: 290.03 (+5.33)

Roka Bioscience (ROKA) in Focus: Stock Surges 19.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 8:11AM CST
Roka Bioscience, Inc. (ROKA) was a big mover last session, as the company saw its shares rise over 19% on the day.
ABMD: 33.48 (-0.12), ROKA: 3.55 (-0.04), EW: 124.55 (+1.60), ANGO: 16.86 (-0.12)

AngioDynamics to Present at Upcoming Investor Conferences
GlobeNewswire - Tue Nov 11, 5:30AM CST
AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today the company will present at the following investor conferences in November:
ANGO: 16.86 (-0.12)

Volcano Posts Narrower-than-Expected Q3 Loss, Guides Low - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 10:10AM CST
Despite Volcano (VOLC) provided disappointing revenue guidance for 2014 on account of expected negative foreign exchange impact, management expects accelerated profitability over the near term.
ABMD: 33.48 (-0.12), VOLC: 10.79 (-0.28), EW: 124.55 (+1.60), ANGO: 16.86 (-0.12)

Strength Seen in DexCom (DXCM): Stocks Gains 14.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 8:46AM CST
DexCom (DXCM) was a big mover last session, with shares rising over 14% on the day.
ABMD: 33.48 (-0.12), DXCM: 53.63 (-0.38), EW: 124.55 (+1.60), ANGO: 16.86 (-0.12)

Hologic Beats Q4 Earnings, Sales as All Segments Gain - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 1:50PM CST
Hologic (HOLX) entered into an amended license agreement with Roka Bioscience, which earned a one-time revenue benefit of $20.1 million for Hologic
ABMD: 33.48 (-0.12), DXCM: 53.63 (-0.38), ANGO: 16.86 (-0.12), HOLX: 26.52 (-0.03)

Thoratec Q3 Earnings & Revenues Lag Estimates, Down Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 9:00AM CST
Following the earnings release, shares of Thoratec Corp. (THOR) declined approximately 3.5% to close at $26.10 yesterday.
ABMD: 33.48 (-0.12), CYNO: 27.20 (-0.20), THOR: 28.40 (+0.48), ANGO: 16.86 (-0.12)

Foundation Medicine Slumps: FMI Tumbles 9.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 7:59AM CST
Foundation Medicine has been witnessing a flat trend in its current year earnings estimate and its share price has been falling for past 24 hours
ABMD: 33.48 (-0.12), DXCM: 53.63 (-0.38), FMI: 24.95 (-0.15), ANGO: 16.86 (-0.12)

Teleflex Beats on Q3 Earnings & Revenues, Outlook Raised - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 1:20PM CST
Teleflex Inc (TFX) reported adjusted earnings of $1.57 per share which outshined both the Zacks Consensus Estimate of $1.37 and year-ago earnings of $1.33.
CYNO: 27.20 (-0.20), FLDM: 29.88 (-0.01), TFX: 114.64 (+0.17), ANGO: 16.86 (-0.12)

Symmetry Medical Q3 Earnings & Revenues Miss, Rise Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 1:10PM CST
Symmetry Medical Inc. (SMA) reported adjusted earnings per share of 11 cents in the third quarter of fiscal 2014, which missed the Zacks Consensus Estimates of 14 cents.
SMA: 9.48 (unch), CYNO: 27.20 (-0.20), FLDM: 29.88 (-0.01), ANGO: 16.86 (-0.12)

CryoLife Q3 Earnings Fall, Revenues Rise Y/Y; Shares Tank - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 1:00PM CST
CryoLife Inc. (CRY) reported adjusted earnings per share of 8 cents in the third quarter of fiscal 2014, lower than the year-ago earnings of 11 cents.
CYNO: 27.20 (-0.20), FLDM: 29.88 (-0.01), CRY: 9.74 (-0.16), ANGO: 16.86 (-0.12)

Mindray Medical Q3 Earnings in Line, 2014 View Lowered - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 2:07PM CST
Mindray Medical International Limited (MR) slashed its 2014 financial guidance in the face of increasing uncertainties in currency and other macro developments that could impact its performance in certain key markets.
ABMD: 33.48 (-0.12), FLDM: 29.88 (-0.01), ANGO: 16.86 (-0.12), MR: 31.22 (-0.27)

Techne Corp. (TECH) Q1 Earnings, Revenues Miss Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 12:50PM CST
Techne Corp. (TECH) reported adjusted earnings of 85 cents per share in the first quarter fiscal 2015, which was lower than the Zacks Consensus Estimate of 87 cents.
CYNO: 27.20 (-0.20), FLDM: 29.88 (-0.01), TECH: 92.10 (+0.08), ANGO: 16.86 (-0.12)

Abiomed Tops Q2 Earnings, Revenues; FY15 Sales View Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 12:10PM CST
Abiomed Inc. (ABMD) reported second-quarter fiscal 2015 earnings of 9 cents per share, outshining the Zacks Consensus Estimate of 2 cents.
ABMD: 33.48 (-0.12), FLDM: 29.88 (-0.01), BEAT: 8.17 (-0.10), ANGO: 16.86 (-0.12)

Becton, Dickinson (BDX) Beats Q4 Earnings, Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 11:03AM CST
Becton, Dickinson and Company (BDX) reported fourth-quarter fiscal 2014 earnings of $1.68 per share, which beat the Zacks Consensus Estimate by 3 cents.
BDX: 129.31 (-0.04), FLDM: 29.88 (-0.01), BEAT: 8.17 (-0.10), ANGO: 16.86 (-0.12)

Accuray (ARAY) Q1 Loss Wider Than Expected, Revenues Lag - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 12:30PM CST
Accuray Inc (ARAY) reported a loss of 28 cents per share in the first quarter of fiscal 2015, wider than the Zacks Consensus Estimate of a loss of 13 cents and a year-ago loss of 21 cents.
ATEC: 1.36 (-0.06), CYNO: 27.20 (-0.20), ARAY: 7.07 (+0.02), ANGO: 16.86 (-0.12)

Greatbatch Beats Q3 Earnings Estimates; Upgrades '14 View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 9:10AM CDT
Based on its third-quarter results, the addition of CCC Medical Devices, and the forecast for the fourth quarter, Greatbatch raised its full-year 2014 revenue and adjusted earnings per share guidance.
ATEC: 1.36 (-0.06), CYNO: 27.20 (-0.20), GB: 49.67 (-0.52), ANGO: 16.86 (-0.12)

Luminex (LMNX) Upgraded to Strong Buy on Impressive Q3 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 5:25PM CDT
Luminex Corporation (LMNX) posted encouraging third-quarter 2014 numbers on Oct 27, with adjusted earnings surpassing the Zacks Consensus Estimate by a wide margin of 120%.
ATEC: 1.36 (-0.06), CYNO: 27.20 (-0.20), LMNX: 18.33 (-0.18), ANGO: 16.86 (-0.12)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Leapora's Taskeen: Redefining Task Accountability

AI's Impact on Workplace Task Management In today’s whirlwind of AI-generated output, transparency is not just a luxury; it’s a necessity. AI systems churn out work that can appear polished but often lacks substance. This doesn't just create headaches; it triggers a ticking bomb in the regulatory department. According to a 2025 survey from Stanford and BetterUp Labs,...

Compass Unveiled: Power Revolution in Private Equity

AI-Driven Insights: Revolutionizing Private Equity Strategies Now this is some spicy news from Huntington Beach! Collective just pulled back the curtain on Compass, their AI-fueled platform that's set to shake up how financial advisors tackle private company equity. If you're an advisor who's sick of staring at nebulous balance sheets filled with unquantifiable private...

HTX's Strategic Moves in Pakistan: A Crypto Frontier

Paving the Way: HTX's Journey in Pakistan Rolling into the Pakistan cryptocurrency scene isn't just a 'walk in the park' for HTX—it's more like traversing a new frontier with an open map. This isn’t some hit-and-run operation; HTX is strategizing for a long haul in one of the liveliest digital market arenas in South Asia. Gathering steam with community AMAs and an X...

FutureVault's AI Agents: Transforming Financial Workflows

Revolutionizing Financial Operations: FutureVault's AI Approach In the dizzying whirlwind of financial services, the launch of FutureVault AI Agents is a game-changer for document management. This isn't some half-baked tool; it's a full-fledged overhaul of how compliance and operations should tick in the modern age. We've all seen it—a paper trail tangled across systems...

Davos Healthcare Aims to Revolutionize Hospital Ratings

Throw away those dusty, old reputation surveys—Davos Healthcare just turned the spotlight onto cold, hard data with its new global hospital evaluation platform. Why Davos Healthcare’s Initiative Matters At the C3 US NYC Davos of Healthcare™ Summit, an event that’s rooted itself alongside the United Nations General Assembly, Davos Healthcare unveiled a...

K-Beauty Takes Front Stage at Target Beauty Studio

Making Waves in the U.S. with K-Beauty SUNGBOON EDITOR and Milk Touch just rolled into Target Beauty Studio, making a splash in the world of K-beauty. From ingredients that boast serious benefits to playful cosmetics that let you express yourself, these brands are shaking up American beauty routines in a big way. Ingredient-Focused Skincare for Every American Face...

Machine Grabs Prime Dallas Property Amid Apartment Boom

Dallas' Hot Market and Machine's Bold Move Well, well, looks like Machine Investment Group's been busy flexing its real estate muscles, bagging a 490-unit gem in North Dallas—your typical, no-frills off-market grab. We’re talking 75 West, nestled in a juicy infill spot, and it’s catching eyes like gold dust in a pan. You don't need me to tell you North Dallas ain't...

Anecdotes by Artists Brings Raw Scent Stories to Sephora

When Maesa pulls back the curtain, they don't just crack it open—they fling it aside with flair. That's precisely what they're doing with their latest venture, Anecdotes by Artists, a fragrance brand that's taking its first bow exclusively at Sephora. It's not your average perfume launch; it's about the stories behind the scents and the artists who craft them. Unveiling...

AI-Driven Lumi Transforms Car Dealership Interactions

Lumi: Changing the Car Buying Game Picture this: You're browsing for a new car, head filled with specifics like towing capacity, price points, and trim options. Usually, such queries would send you bouncing around the web, but Lectrium's Lumi promises to keep the questioning—and decision-making—right on the dealership's page. In a move set to shake up the game,...

Succession Planning in Turmoil: Only 42% Ready

Diving into the Succession Crisis in Finance Succession planning in the financial advisory space is like retirement planning for the rest of us—everyone knows it's crucial, yet too many put it off. Despite the looming retirement wave and desperate interest from the younger cohort, a staggering 42% of financial advisors are still without a documented succession game...